GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Cyclically Adjusted Revenue per Share

Biogen (BUE:BIIB) Cyclically Adjusted Revenue per Share : ARS8,000.60 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Biogen Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biogen's adjusted revenue per share for the three months ended in Mar. 2025 was ARS17,677.598. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ARS8,000.60 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Biogen's average Cyclically Adjusted Revenue Growth Rate was 3.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 15.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biogen was 53.80% per year. The lowest was 8.30% per year. And the median was 21.50% per year.

As of today (2025-06-28), Biogen's current stock price is ARS11675.00. Biogen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ARS8,000.60. Biogen's Cyclically Adjusted PS Ratio of today is 1.46.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogen was 17.28. The lowest was 1.45. And the median was 5.56.


Biogen Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Biogen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cyclically Adjusted Revenue per Share Chart

Biogen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 577.47 952.00 1,791.82 5,538.01 6,998.03

Biogen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,367.22 8,035.49 7,416.61 6,998.03 8,000.60

Competitive Comparison of Biogen's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PS Ratio falls into.


;
;

Biogen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=17677.598/134.9266*134.9266
=17,677.598

Current CPI (Mar. 2025) = 134.9266.

Biogen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 99.913 100.684 133.894
201509 112.290 100.392 150.918
201512 166.511 99.792 225.135
201603 181.588 100.470 243.863
201606 184.413 101.688 244.692
201609 200.961 101.861 266.196
201612 209.808 101.863 277.910
201703 200.707 102.862 263.272
201706 239.193 103.349 312.277
201709 254.645 104.136 329.939
201712 297.724 104.011 386.217
201803 298.009 105.290 381.893
201806 403.816 106.317 512.483
201809 626.804 106.507 794.058
201812 664.132 105.998 845.385
201903 692.468 107.251 871.160
201906 848.690 108.070 1,059.604
201909 1,093.047 108.329 1,361.414
201912 1,232.155 108.420 1,533.392
202003 1,267.311 108.902 1,570.171
202006 1,566.453 108.767 1,943.196
202009 1,594.413 109.815 1,959.012
202012 1,506.454 109.897 1,849.560
202103 1,593.405 111.754 1,923.796
202106 1,751.338 114.631 2,061.408
202109 1,828.539 115.734 2,131.767
202112 1,871.773 117.630 2,147.012
202203 1,841.765 121.301 2,048.648
202206 2,130.960 125.017 2,299.876
202209 2,407.155 125.227 2,593.614
202212 2,933.298 125.222 3,160.631
202303 3,351.003 127.348 3,550.430
202306 4,051.134 128.729 4,246.184
202309 6,115.183 129.860 6,353.797
202312 5,904.416 129.419 6,155.667
202403 13,226.500 131.776 13,542.709
202406 15,128.978 132.554 15,399.797
202409 16,042.045 133.029 16,270.890
202412 16,992.783 133.157 17,218.597
202503 17,677.598 134.927 17,677.598

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Biogen  (BUE:BIIB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biogen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=11675.00/8000.60
=1.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogen was 17.28. The lowest was 1.45. And the median was 5.56.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biogen Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Cyclically Adjusted Revenue per Share
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.